Inhibition of Neu-Induced Mammary Carcinogenesis in Transgenic Mice Expressing ERΔ3, a Dominant Negative Estrogen Receptor α Variant

Hormones and Cancer

Volumn 3, Issue 5-6, 2012, Pages 227-239

  Davis, Vicki L ^a,b,c,e   Shaikh, Firdos ^b   Gallagher, Katie M ^a   Villegas, Michael ^b   Rea, Sheri L ^a   Cline, J Mark ^c   Hughes, Claude L ^b,c,d  

^a DUQUESNE UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d IQVIA   (United States)

^e CLARION UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ISOFLAVONE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 84869086671     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0122-x     Document Type: Article

References (55)

1. Herynk MH, Fuqua SAW (2004) Estrogen receptor mutations in human disease. Endocr Rev 25: 869-898.
2. Desai AJ, Luqmani YA, Walters JE, Coope RC, Dagg B, Gomm JJ, Pace PE, Rees CN, Thirunavukkarasu V, Shousha S, Groome NP, Coombes R, Ali S (1997) Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. Br J Cancer 75: 1173-1184.
3. Park W, Choi JJ, Hwang ES, Lee JH (1996) Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. Clin Cancer Res 2: 2029-2035.
4. Fasco MJ, Amin A, Pentecost BT, Yang Y, Gierthy JF (2003) Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol 206: 33-47.
5. Han F, Miksicek R, Clarke R, Conrad SE (2004) Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. J Mol Endocrinol 32: 935-945.
6. Wang Y, Miksicek RJ (1991) Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 5: 1707-1715.
7. Bollig A, Miksicek RJ (2000) An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol 14: 634-649.
8. Erenburg I, Schachter B, Mira y Lopez R, Ossowski L (1997) Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol 11: 2004-2015.
9. Leygue E, Dotzlaw H, Watson PH, Murphy LC (2000) Altered expression of estrogen receptor-alpha variant messenger RNAs between adjacent normal breast and breast tumor tissues. Breast Cancer Res 2: 64-72.
10. Kim K, Thu N, Saville B, Safe S (2003) Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol Endocrinol 17: 804-817.
11. Davis VL, Newbold RR, Couse JF, Rea SL, Gallagher KM, Goulding EH, Jefferson W, Eddy EM, Bullock BC, Korach KS (2012) Expression of a dominant negative estrogen receptor alpha variant in transgenic mice accelerates uterine cancer induced by the potent estrogen diethylstilbestrol. Reprod Toxicol doi: 10. 1016/j. reprotox. 2012. 08. 005.
12. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-10582.
13. Cardiff RD, Wellings SR (1999) The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 4: 105-122.
14. Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A (2000) Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 60: 273-275.
15. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Iezzi M, Ricci C, Astolfi A, Croci S, Marangoni F, Musiani P, Forni G, Lollini P-L (2003) Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 105: 384-389.
16. Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K, McKimmey C, Liu N, Thor A (2005) Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 65: 879-886.
17. Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A, Murthy S, Thor AD (2003) Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 63: 2425-2433.
18. Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA (2006) Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene 25: 3325-3334.
19. Kumar V, Chambon P (1988) The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55: 145-156.
20. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300.
21. Messina M, McCaskill-Stevens W, Lampe JW (2006) Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 98: 1275-1284.
22. Bouker KB, Hilakivi-Clarke L (2000) Genistein: does it prevent or promote breast cancer? Environ Health Perspect 108: 701-708.
23. Jin Z, MacDonald RS (2002) Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 132: 3186-3190.
24. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN (2002) Chemoprevention of breast cancer: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 137: 59-69.
25. Nagata C (2010) Factors to consider in the association between soy isoflavone intake and breast cancer risk. J Epidemiol 20: 83-89.
26. Setchell KDR, Brown NM, Zhao X, Lindley SL, Heubi JE, King EC, Messina MJ (2011) Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 94: 1284-1294.
27. Davis VL, Jayo MJ, Ho A, Kotlarczyk MP, Hardy ML, Foster WG, Hughes CL (2008) Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 68: 8377-8383.
28. Lindholm J, van Diest PJ, Haffner D, Mikuz G, Wegner AR (1992) A morphometric filter improves the diagnostic value of morphometric analyses of frozen histopathological sections from mammary tumours. Anal Cell Pathol 4: 443-449.
29. Parsa P, Parsa B (2009) Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pac J Cancer Prev 10: 545-550.
30. Varayoud J, Ramos JG, Monje L, Bosquiazzo V, Munoz-de-Toro M, Luque EH (2005) The estrogen receptor alpha sigma3 mRNA splicing variant is differentially regulated by estrogen and progesterone in the rat uterus. J Endocrinol 186: 51-60.
31. Mitchell DC, Ing NH (2003) Estradiol stabilizes estrogen receptor messenger ribonucleic acid in sheep endometrium via discrete sequence elements in its 3′-untranslated region. Mol Endocrinol 17: 562-574.
32. Leygue ER, Watson PH, Murphy LC (1996) Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 88: 284-290.
33. Chappell SA, Johnson SM, Shaw JA, Walker RA (2000) Expression of oestrogen receptor alpha variants in non-malignant breast and early invasive breast carcinomas. J Pathol 192: 159-165.
34. van Dijk MA, Hart AA, van 't Veer LJ (2000) Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res 60: 530-533.
35. Chaidarun SS, Klibanski A, Alexander JM (1997) Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. J Clin Endocrinol Metab 82: 1058-1065.
36. Fata JE, Chaudhary V, Khokha R (2001) Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod 65: 680-688.
37. Going JJ, Anderson TJ, Battersby S, MacIntyre CC (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193-204.
38. Petz LN, Nardulli AM (2000) Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 14: 972-985.
39. Petz LN, Ziegler YS, Loven MA, Nardulli AM (2002) Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143: 4583-4591.
40. Schultz JR, Petz LN, Nardulli AM (2005) Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 280: 347-354.
41. Jakacka M, Ito M, Martinson F, Ishikawa T, Lee EJ, Jameson JL (2002) An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. Mol Endocrinol 16: 2188-2201.
42. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
43. Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456.
44. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A (2002) Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 132: 552S-558S.
45. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L (2008) The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer 98: 1485-1493.
46. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF (2005) Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res 65: 3396-3403.
47. Yan L, Li D, Yee JA (2002) Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. Clin Exp Metastasis 19: 535-540.
48. Chiesa G, Rigamonti E, Lovati MR, Disconzi E, Soldati S, Sacco MG, Cato EM, Patton V, Scanziani E, Vezzoni P, Arnoldi A, Locati D, Sirtori CR (2008) Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. Mol Nutr Food Res 52: 1121-1129.
49. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
50. Hou Y-F, Yuan S-T, Li H-C, Wu J, Lu J-S, Liu G, Lu L-J, Shen Z-Z, Ding J, Shao Z-M (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23: 5799-5806.
51. Markey GC, Cullen R, Diggin P, Hill ADK, Mc Dermott EW, O'Higgins NJ, Duffy MJ (2009) Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer. Tumour Biol 30: 171-175.
52. Qui W-S, Yue L, Ding A-P, Sun J, Yao Y, Shen Z, Fan L-H (2009) Co-expression of ER-beta and HER2 associated with poorer prognosis in primary breast cancer. Clin Invest Med 32: E250-260.
53. Salvatori L, Pallante P, Ravenna L, Chinzari P, Frati L, Russo MA, Petrangeli E (2003) Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site. Oncogene 22: 4875-4881.
54. Dampier K, Hudson EA, Howells LM, Manson MM, Walker RA, Gescher A (2001) Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. Br J Cancer 85: 618-624.
55. Lau TY, Leung LK (2006) Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells. Br J Nutr 96: 169-176.